✦ LIBER ✦

PND35 Belgian Cost-Utility Analysis of Gilenya® (Fingolimod) in the Management of Adults with Active Relapsing Remitting Multiple Sclerosis

✍ Scribed by S. Drieskens; K. Moeremans

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND33 Cost Minimization Analysis of Fing

✍ B. Verheggen; M. Treur; M. Groot 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PND30 Cost Analysis of Glatiramer Acetat

✍ Sánchez-de la Rosa, R.; Sabater, E.; Casado, M.A. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost analysis of glatiramer acetate vs.

✍ Rainel Sanchez-de la Rosa, Eliazar Sabater, Miguel A Casado 📂 Article 📅 2013 🏛 Springer-Verlag 🌐 English ⚖ 206 KB

Cost-utility of interferon β1bin the tre

✍ G. Kobelt; L. Jönsson; S. Fredrikson 📂 Article 📅 2003 🏛 Springer 🌐 French ⚖ 346 KB

PNP15: COST-UTILITY ANALYSIS OF THE TREA

✍ C Rubio-Terrés; F Medina; I Aristegui; G Izquierdo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PND13 A COST-EFFECTIVENESS ANALYSIS OF N

✍ R Gani; ER Samuels; S Hughes; G Giovanonni 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB